Initial indicators for the prognosis of Acinetobacter Baumannii bacteremia in children.
Bacteremia
Children; Acinetobacter baumannii
Mortality
Risk factors
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 Sep 2023
29 Sep 2023
Historique:
received:
09
06
2023
accepted:
24
09
2023
medline:
4
10
2023
pubmed:
30
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
Risk factors related to mortality due to Acinetobacter baumannii (AB) bacteremia have been unveiled previously, but early clinical manifestations of AB bacteremia based on prognosis remain uncovered. The demographic characteristics, clinical features, antibiotic susceptibility, and outcomes of 37 hospitalized children with laboratory-confirmed AB bacteremia from Suzhou, China, were collected and analyzed retrospectively. Of the 37 children with AB bacteremia included in this study, 23 were males and 14 were females, with a median age of 4.83 (0.60 to 10.15) years. Among the children, 18 died (48.65%, 18/37) and 19 survived (51.35%, 19/37). The dead group had a significantly higher incidence of respiratory failure (p = 0.008), shock (P = 0.000), MODS (p = 0.000), neutropenia (< 1.5 × 10 AB bacteremia has a high mortality in children, especially in patients with hematological diseases and oncology. Many early indicators were associated with poor prognosis, while elevated CRP and neutropenia were the independent predictors for the 30-day mortality of children with laboratory-confirmed AB bacteremia.
Sections du résumé
BACKGROUND
BACKGROUND
Risk factors related to mortality due to Acinetobacter baumannii (AB) bacteremia have been unveiled previously, but early clinical manifestations of AB bacteremia based on prognosis remain uncovered.
METHODS
METHODS
The demographic characteristics, clinical features, antibiotic susceptibility, and outcomes of 37 hospitalized children with laboratory-confirmed AB bacteremia from Suzhou, China, were collected and analyzed retrospectively.
RESULTS
RESULTS
Of the 37 children with AB bacteremia included in this study, 23 were males and 14 were females, with a median age of 4.83 (0.60 to 10.15) years. Among the children, 18 died (48.65%, 18/37) and 19 survived (51.35%, 19/37). The dead group had a significantly higher incidence of respiratory failure (p = 0.008), shock (P = 0.000), MODS (p = 0.000), neutropenia (< 1.5 × 10
CONCLUSIONS
CONCLUSIONS
AB bacteremia has a high mortality in children, especially in patients with hematological diseases and oncology. Many early indicators were associated with poor prognosis, while elevated CRP and neutropenia were the independent predictors for the 30-day mortality of children with laboratory-confirmed AB bacteremia.
Identifiants
pubmed: 37775747
doi: 10.1186/s12879-023-08639-5
pii: 10.1186/s12879-023-08639-5
pmc: PMC10542241
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
640Subventions
Organisme : Natural Science Foundation of Jiangsu Province
ID : BK20211077
Organisme : Natural Science Foundation of Jiangsu Province
ID : BK20210097
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1073-1081
pubmed: 28101785
Front Cell Infect Microbiol. 2020 Sep 14;10:486
pubmed: 33042864
Pediatr Crit Care Med. 2020 Feb;21(2):e52-e106
pubmed: 32032273
Infect Drug Resist. 2022 Sep 12;15:5401-5409
pubmed: 36119640
Leuk Lymphoma. 2019 Nov;60(11):2787-2792
pubmed: 31014145
J Clin Microbiol. 2021 Nov 18;59(12):e0021321
pubmed: 34550809
J Microbiol Immunol Infect. 2012 Oct;45(5):356-62
pubmed: 22575430
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6673-6678
pubmed: 27572416
Clin Microbiol Rev. 2021 Mar 10;34(2):
pubmed: 33692149
Infect Control Hosp Epidemiol. 2014 Jul;35(7):753-71
pubmed: 24915204
Antibiotics (Basel). 2020 Apr 23;9(4):
pubmed: 32340386
Curr Opin Infect Dis. 2014 Feb;27(1):102-7
pubmed: 24345923
BMC Infect Dis. 2016 Aug 09;16:386
pubmed: 27506948
J Infect. 2019 Aug;79(2):130-138
pubmed: 31145911
BMC Infect Dis. 2021 Aug 20;21(1):841
pubmed: 34416851
J Med Microbiol. 2020 Jul;69(7):949-959
pubmed: 32584215
Microbiol Res. 2021 Jun;247:126722
pubmed: 33618061
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3127-31
pubmed: 26883694
Int J Mol Sci. 2019 Jul 16;20(14):
pubmed: 31315248
Infect Immun. 2011 Aug;79(8):3317-27
pubmed: 21576323
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9599-604
pubmed: 27506797
Zhonghua Yi Xue Za Zhi. 2012 Jan 10;92(2):76-85
pubmed: 22490686
Medicine (Baltimore). 2016 Mar;95(9):e2943
pubmed: 26945403
Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):2063-8
pubmed: 26205665
Intensive Care Med. 2012 Dec;38(12):1930-45
pubmed: 23011531
Microb Drug Resist. 2019 Oct;25(8):1210-1218
pubmed: 31120349
Diagn Microbiol Infect Dis. 2021 Feb;99(2):115229
pubmed: 33161239
Mol Biol Rep. 2021 Oct;48(10):6987-6998
pubmed: 34460060
J Infect Dev Ctries. 2022 Sep 30;16(9):1473-1481
pubmed: 36223624
J Appl Microbiol. 2023 Feb 16;134(2):
pubmed: 36597783
J Infect Dev Ctries. 2014 Aug 13;8(8):1049-54
pubmed: 25116673
Top Spinal Cord Inj Rehabil. 2019 Summer;25(3):228-240
pubmed: 31548790
JAMA. 2020 Jun 2;323(21):2160-2169
pubmed: 32484534
Pathogens. 2021 Mar 24;10(4):
pubmed: 33804894
Am J Infect Control. 2016 Apr 1;44(4):e37-9
pubmed: 26804303